Proteolix reports encouraging results from Phase I cancer trial
The Phase I clinical trial was designed to assess the safety, pharmacokinetics and pharmacodynamics of carfilzomib among patients with advanced solid tumors who had previously failed at least
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.